Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CFO Oluyemi Okupe sold 11,581 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $43.01, for a total value of $498,098.81. Following the completion of the transaction, the chief financial officer now owns 107,789 shares of the company’s stock, valued at $4,636,004.89. The trade was a 9.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Oluyemi Okupe also recently made the following trade(s):
- On Tuesday, February 4th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $38.92, for a total value of $450,732.52.
- On Monday, January 13th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.44, for a total value of $283,039.64.
- On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.98, for a total value of $126,305.74.
- On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.77, for a total value of $488,573.43.
- On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total value of $3,021,032.66.
- On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98.
Hims & Hers Health Trading Up 28.4 %
Hims & Hers Health stock opened at $59.49 on Friday. The firm has a market capitalization of $13.00 billion, a P/E ratio of 135.20 and a beta of 1.35. Hims & Hers Health, Inc. has a 1 year low of $9.22 and a 1 year high of $59.55. The business has a 50-day moving average of $31.53 and a 200-day moving average of $23.99.
Hedge Funds Weigh In On Hims & Hers Health
Analyst Ratings Changes
HIMS has been the subject of a number of analyst reports. TD Cowen reissued a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. BTIG Research initiated coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Canaccord Genuity Group raised their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Finally, Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.13.
Check Out Our Latest Stock Report on HIMS
Hims & Hers Health Company Profile
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Featured Stories
- Five stocks we like better than Hims & Hers Health
- Investing in Travel Stocks Benefits
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Why is the Ex-Dividend Date Significant to Investors?
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- How to Invest in Biotech Stocks
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.